Corporate Profile

La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.
Featured Documents
June 16, 2018
A Phase 1, Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of LJPC-401
June 16, 2018
EHA Poster
December 22, 2017
GIAPREZA™ (angiotensin II) Update

Share Price

Price
Change (%)  (%)
Volume
Data as of

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events
There are currently no events scheduled.
Recent News
La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118 for the Treatment of Severe Malaria
Apr 24, 2019
-Designation offers potential for expedited development and review, and highlights the urgent need for additional treatment options for patients suffering from severe malaria- - NDA Planned for LJPC-0118 for Fourth Quarter of 2019 - SAN DIEGO , April 24, 2019 (GLOBE NEWSWIRE) -- La Jolla
Read More →
La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer
Mar 11, 2019
SAN DIEGO , March 11, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the
Read More →
La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference
Mar 07, 2019
SAN DIEGO , March 07, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that
Read More →